

Ardea Biosciences, Inc./DE
Form 5
June 07, 2007

FORM 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box if
no longer subject
to Section 16.
Form 4 or Form
5 obligations
may continue.
See Instruction
1(b).
Form 3 Holdings
Reported
Form 4
Transactions
Reported

**ANNUAL STATEMENT OF CHANGES IN BENEFICIAL
OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0362
Expires: January 31,
2005
Estimated average
burden hours per
response... 1.0

1. Name and Address of Reporting Person *
ANDREEFF DANE

(Last) (First) (Middle)

C/O ANDREEFF EQUITY
ADVISORS LLC, 450 LAUREL
ST STE 2105

(Street)

BATON ROUGE, LA 70801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading
Symbol
Ardea Biosciences, Inc./DE [ARDC]

3. Statement for Issuer's Fiscal Year Ended
(Month/Day/Year)
12/31/2006

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

____ Director ____X____ 10% Owner
____ Officer (give title below) ____ Other (specify below)

6. Individual or Joint/Group Reporting

(check applicable line)

__X__ Form Filed by One Reporting Person
____ Form Filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/02/2007	Â	S4	16,350 D \$ 4.758	1,203,848	I	See footnote (1)
Common Stock	02/13/2006 ⁽³⁾	Â	P4	71,932 A \$ 3.5	1,203,848	I	See footnote (2)
Common Stock	04/03/2006	Â	P4	2,795 A \$ 3.54	1,203,848	I	See footnote

Edgar Filing: Ardea Biosciences, Inc./DE - Form 5

									(2)
Common Stock	04/04/2006	Â	P4	1,993	A	\$ 3.55	1,203,848	I	See footnote (2)
Common Stock	04/05/2006	Â	P4	10,164	A	\$ 3.55	1,203,848	I	See footnote (2)
Common Stock	04/10/2006	Â	P4	8,244	A	\$ 3.61	1,203,848	I	See footnote (2)
Common Stock	04/11/2006	Â	P4	2,886	A	\$ 3.62	1,203,848	I	See footnote (2)
Common Stock	04/17/2006	Â	P4	8,733	A	\$ 3.65	1,203,848	I	See footnote (2)
Common Stock	04/18/2006	Â	P4	1,561	A	\$ 3.65	1,203,848	I	See footnote (2)
Common Stock	04/19/2006	Â	P4	4,698	A	\$ 3.65	1,203,848	I	See footnote (2)
Common Stock	04/20/2006	Â	P4	299	A	\$ 3.65	1,203,848	I	See footnote (2)
Common Stock	04/21/2006	Â	P4	1,292	A	\$ 3.65	1,203,848	I	See footnote (2)
Common Stock	11/01/2006	Â	P4	17,526	A	\$ 3.9899	1,203,848	I	See footnote (2)
Common Stock	01/03/2007	Â	P4	20,165	A	\$ 4.36	1,203,848	I	See footnote (2)
Common Stock	01/08/2007	Â	P4	2,400	A	\$ 4.7	1,203,848	I	See footnote (2)
Common Stock	04/30/2007	Â	P4	8,333	A	\$ 5.4766	1,203,848	I	See footnote (2)
Common Stock	05/02/2007	Â	P4	163	A	\$ 5.51	1,203,848	I	See footnote (2)

Edgar Filing: Ardea Biosciences, Inc./DE - Form 5

Common Stock	05/02/2007	Â	P4	2,991	A	\$ 5.5	1,203,848	I	See footnote (2)
Common Stock	05/01/2006	Â	S4	9,750	D	\$ 3.55	1,203,848	I	See footnote (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 2270
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. of Derivative Securities (Instr. 5)
					(A) (D)	Date Exercisable Expiration Date	Title Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

ANDREEFF DANE
C/O ANDREEFF EQUITY ADVISORS LLC
450 LAUREL ST STE 2105
BATON ROUGE, LA 70801

Â Â X Â Â

Signatures

/s/ Dane
Andreeff 06/07/2007

**Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This transaction was made by a fund that is not, itself, a 10% owner of the issuer's securities. The reporting person is reporting this transaction because he is the managing member of the fund's general partner and thus may be deemed an indirect beneficial owner of the

Edgar Filing: Ardea Biosciences, Inc./DE - Form 5

fund's holdings. When these holdings are aggregated with the reporting person's other indirect holdings of this issuer's securities, he may be deemed an indirect beneficial owner of 10% or more of the issuer's securities.

(2) This transaction was made by a fund that is not, itself, a 10% owner of the issuer's securities. The reporting person is reporting this transaction because he is a Director of the fund and thus may be deemed an indirect beneficial owner of the fund's holdings. When these holdings are aggregated with the reporting person's other indirect holdings of this issuer's securities, he may be deemed an indirect beneficial owner of 10% or more of the issuer's securities.

(3) The reporting person may be deemed to have become a 10% owner of the issuer's securities on this date. These holdings were reportable on a Form 3. The SEC's reporting system would not accept that form type to be listed in Table 1 of this Form 5 filing.

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.